Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 27, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Immunotoxin WPD101a as a Potential Drug Candidate for Targeted Therapy in Muscle Invasive Bladder Cancer Expressing

Aleksandra Klimczak1, Agnieszka Krawczenko1, Sandra Stamnitz1

  • 1Laboratory of Biology of Stem and Neoplastic Cells, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.

International Journal of Molecular Sciences
|June 26, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chondrogenic Potential of Human Adipose-Derived Stem/Stromal Cells (hAD-MSCs) and Human Dental Pulp Stem/Stromal Cells (hDPSCs) Growing on a Poly L-Lactide-<i>Co</i>-Caprolactone Scaffold (PLCL).

Cells·2026
Same author

Mesenchymal Stem Cell Secretome for Cardiac Regeneration: Opportunity for Cell-Free Therapy.

International journal of molecular sciences·2026
Same author

Combined TGF-β3 and FGF-2 Stimulation Enhances Chondrogenic Potential of Ovine Bone Marrow-Derived MSCs.

Cells·2025
Same author

Crystal structure and polymorphic forms of auranofin revisited.

RSC advances·2025
Same author

Assessing Cardiovascular Risk Among Polish Soldiers: Insights Using the POL SCORE Tool.

Journal of clinical medicine·2025
Same author

Potent Biological Activity of Fluorinated Derivatives of 2-Deoxy-d-Glucose in a Glioblastoma Model.

Biomedicines·2024

This study shows WPD101a immunotoxin effectively targets interleukin-13 receptor subunit alpha 2 (IL-13Rα2) expressing bladder cancer cells, inducing apoptosis and inhibiting growth. This offers a promising therapeutic strategy for muscle invasive bladder cancer (MIBC).

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Muscle invasive bladder cancer (MIBC) therapy often fails due to tumor heterogeneity and resistance.
  • Interleukin-13 receptor subunit alpha 2 (IL-13Rα2) is a potential therapeutic target as it is expressed on bladder cancer cells but not normal urothelial cells.

Purpose of the Study:

  • To investigate the therapeutic efficacy of WPD101a immunotoxin against IL-13Rα2-expressing bladder cancer (BC) cells.
  • To evaluate the impact of WPD101a on BC cell phenotype, viability, proliferation, and apoptosis in vitro using 2D and 3D models.

Main Methods:

  • Assessed IL-13Rα2 expression using flow cytometry, immunofluorescence, and Western blot.
  • Evaluated WPD101a's biological effects on cell viability, proliferation (MTT, SRB, CellTiter-Glo, Live/Dead assays), and apoptosis (Annexin V/PI staining, qRT-PCR of CASP genes).
Keywords:
IL-13Rα2MIBCbladder cancerimmunotoxininterleukin 13 receptor subunit alpha 2muscle-invasive bladder cancertargeted therapy

More Related Videos

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

Related Experiment Videos

Last Updated: Jun 27, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model
06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

  • Utilized both 2-dimensional (2D) and 3-dimensional (3D) cell culture models.

    • Main Results:

    • BC cell lines TCC-SUP, JMSU-1, and UM-UC-3 expressed IL-13Rα2, while RT-4, HCV-29, and 5637 did not.
    • WPD101a demonstrated sensitivity at lower concentrations (0.1 ng/mL) in 2D models versus 3D models (1.0 ng/mL) for IL-13Rα2-expressing cells.
    • IL-13Rα2-negative cells remained resistant; WPD101a induced apoptosis and inhibited growth in IL-13Rα2-positive cells, confirmed by cell cycle analysis and CASP gene expression.

    Conclusions:

    • WPD101a exhibits receptor-dependent cytotoxic effects specifically against IL-13Rα2-expressing bladder cancer cells.
    • The immunotoxin effectively inhibits growth and induces apoptosis in MIBC cells, highlighting its potential as a targeted therapy.
    • WPD101a demonstrates specificity and efficacy, offering a novel therapeutic avenue for bladder cancer treatment.